Despite Flat Q2, Sanofi Foresees Growth In H2, Fuelled by IO And Rare Blood Units

CEO also says there's still room for more M&A, and that Sanofi is a virtual paragon of US pricing restraint that rivals can learn from.

SC1807_Bizman Telescope_662264896_1200.jpg
Sanofi CEO Sees Growth Coming, Boosted By Ablynx and Bioverativ Buys • Source: Shutterstock

Shrugging off further declines in its diabetes business during the second quarter, Sanofi's CEO Olivier Brandicourt used the French group's half-year update to predict a turnaround in the French group's fortunes starting with a resumption of growth in the second half, fueled not by price increases but rather by its rare blood disorder and new immunology businesses.

Presenting the second-quarter performance - which saw continued declines in its troubled diabetes segment that was largely offset by its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.